Sector
PharmaceuticalsOpen
₹128.95Prev. Close
₹130.35Turnover(Lac.)
₹192.05Day's High
₹132.89Day's Low
₹128.1352 Week's High
₹147.252 Week's Low
₹81.85Book Value
₹153.94Face Value
₹10Mkt Cap (₹ Cr.)
771.14P/E
5.3EPS
24.63Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 59.81 | 59.81 | 59.81 | 59.81 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 615.54 | 572.75 | 578.89 | 584.8 |
Net Worth | 675.35 | 632.56 | 638.7 | 644.61 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 856.57 | 751.83 | 731.29 | 693.71 |
yoy growth (%) | 13.93 | 2.8 | 5.41 | 8.6 |
Raw materials | -424.99 | -378.84 | -375.06 | -395.81 |
As % of sales | 49.61 | 50.38 | 51.28 | 57.05 |
Employee costs | -104.16 | -100.37 | -89.3 | -71.61 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 16.11 | -19.56 | 30.51 | -50.85 |
Depreciation | -87.29 | -90.05 | -86.61 | -88.25 |
Tax paid | -20.51 | -1.22 | -10.95 | 16.46 |
Working capital | 24.4 | 224.01 | -12.39 | -206.93 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.93 | 2.8 | 5.41 | 8.6 |
Op profit growth | 27.14 | 11.71 | 20.97 | -3.11 |
EBIT growth | 32.31 | 49.44 | 56.9 | -0.94 |
Net profit growth | -78.84 | -217.94 | -144.36 | -32.51 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,280.9 | 1,207.31 | 1,038.73 | 891.34 | 779.64 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,280.9 | 1,207.31 | 1,038.73 | 891.34 | 779.64 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 431.96 | 33.5 | 43.5 | 22.7 | 33.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
N R Munjal
Joint Managing Director
Himanshu Jain
Company Sec. & Compli. Officer
Pradeep Verma
Executive Director
Rishav Mehta
Independent Director
S P Sharma
Independent Director
Neerja Chathley
Independent Director
Ashwani K Vig
Executive Director
Sahil Munjal
Independent Director
Rajendra Kumar Gupta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ind-Swift Laboratories Ltd
Summary
Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.Ind-Swift Laboratories Ltd was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they enter
Read More
The Ind-Swift Laboratories Ltd shares price on N/A is Rs.₹130.15 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Laboratories Ltd is ₹769.02 Cr. as of 22 Jul ‘24
The PE and PB ratios of Ind-Swift Laboratories Ltd is 5.3 and 1.04 as of 22 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Ind-Swift Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Laboratories Ltd is ₹82 and ₹147.1 as of 22 Jul ‘24
Ind-Swift Laboratories Ltd's CAGR for 5 Years at 34.04%, 3 Years at 2.50%, 1 Year at 43.73%, 6 Month at 22.26%, 3 Month at 10.15% and 1 Month at 16.37%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.